← All trials
NCT04685135
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Aug 31, 2023
- First posted
- Dec 28, 2020
- Last posted
- Dec 28, 2020
- Enrollment
- 452
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Mirati Therapeutics Inc.Lead sponsor
- Mirati Therapeutics Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.